InscoBio announced on the 7th that its bio research and development affiliate, InsBioPharm, has signed a technology transfer agreement with Sogang University regarding 'Lipid Nanocomposites and Lipid Nanoparticles for Genetic Material Delivery to Establish a Drug Delivery System (DDS)'.


Through this technology transfer, InscoBio plans to strengthen its expertise in the development of nano pharmaceuticals. It intends to establish an industry-academia cooperation system based on the specialized knowledge and know-how in drug delivery and genetic material delivery possessed by Sogang University.


InsBioPharm aims to develop high-efficiency and high-efficacy drug delivery and genetic material delivery therapeutics through mutual cooperation with Sogang University. The transferred technology includes lipid nanocomposite-based drug delivery technology and lipid nanoparticle technology for genetic material delivery, which will be applied to InsBioPharm’s melittin-based nano pharmaceutical platform technology development.


Through this, InsBioPharm expects to develop optimal drug delivery routines according to indications, thereby increasing the success rate of personalized therapeutic development via drug delivery and genetic material delivery.


Currently, securing drug delivery carriers for stable in vivo drug delivery is a key factor in therapeutic development worldwide. InsBioPharm plans to actively target the cell and gene therapy market by developing a platform based on melittin-based drug delivery therapeutics and delivery carrier technology for genetic material delivery.



A company representative explained, “We plan to maximize synergy based on proven technology through this technology transfer agreement and the establishment of an industry-academia cooperation system,” adding, “This will accelerate the development of new nano pharmaceutical drugs.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing